BeOne Medicines (ONC) Short term Debt (2015 - 2026)

BeOne Medicines (ONC) has 11 years of Short term Debt data on file, last reported at $116.1 million in Q1 2026.

• On a quarterly basis, Short term Debt fell 84.79% year-over-year to $116.1 million in Q1 2026; TTM through Mar 2026 was $116.1 million, a 84.79% decrease from a year earlier, with the FY2025 full-year figure at $57.3 million, down 93.27% from the prior year.
• Short term Debt for Q1 2026 stood at $116.1 million, up from $57.3 million in the prior quarter.
• Over the last five years, Short term Debt for ONC reached as high as $863.8 million in Q3 2024 and fell as low as $50.0 million in Q4 2022.
• Historically, Short term Debt has averaged $481.8 million across 5 years, with a median of $421.1 million in 2023.
• Across the five-year window, Short term Debt jumped 1276.73% in 2023 and sank 93.95% in 2025, its largest moves.
• Year by year, Short term Debt stood at $50.0 million in 2022, then soared by 1276.73% to $688.4 million in 2023, then climbed by 23.7% to $851.5 million in 2024, then tumbled by 93.27% to $57.3 million in 2025, then surged by 102.71% to $116.1 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $116.1 million in Q1 2026, $57.3 million in Q4 2025, and $52.2 million in Q3 2025.